Bayer HealthCare's mission is to provide new treatment options for diseases with high unmet medical need. Bayer HealthCare is committed to innovation and to translating ideas from basic research into novel drugs and also dedicated to fostering collaborations with excellent academic groups and start-ups.
Bayer HealthCare is interested in novel targets and disease-related biomarkers in the fields of:
■Oncology - Focus on anti-proliferative, survival signaling, transcription and chromatin modulation, cell cycle regulation, tumor metabolism, hypoxia, immunotherapy and antibody-drug conjugates.
■Gynecology - Focus on novel treatment options for endometriosis (incl. adenomyosis uteri/endometriosis interna) and uterine fibroids (uterine leiomyoma).
■Cardiology - Focus on novel approaches to the care of chronic and/or acute pulmonary hypertension, atrial fibrillation, heart failure, acute coronary syndrome, ischemic stroke, peripheral arterial occlusive disease, acute lung injury/adult respiratory distress syndrome, cardiorenal syndrome and chronic kidney diseases.
■Hematology - Focus on hemophelia, anemia and thrombocytopenia.
The current call for proposals is limited to the above-mentioned indications, treatment paradigms and approaches (small-molecular-weight compounds, antibodies, recombinant proteins). In this call we will not fund proposals with approaches outside the above-mentioned areas, e.g. in gene or cell therapy, vaccination or unspecific approaches without defined molecular targets.
Funding Information
There are two different types of grants:
- Support Grants (€5,000-€10,000)
- To further advance research on targets which are at a very early stage of discovery
- Focus Grants(€10,000-€125,000)
- For more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug-discovery process.
The size of the individual grant will depend on the target specifics and the phase of validation, but is limited to a maximum of €125,000.
Special conditions may apply for proprietary targets and the in-licensing of targets. Grant types do not need to be selected by the grant applicant. The decision on grant allocation is made at the sole and absolute discretion of Bayer HealthCare.
In addition to the financial support, successful applicants may benefit from the complementary expertise. Bayer HealthCare has a long-standing experience in drug discovery and development as well as a proven track record of collaborations with academic institutes, start-ups, and biotech companies.
Please visit Bayer HealthCare website for more details.
Eligibility
Researchers from universities, other academic research institutes and start-up companies from all over the world.
Schedule of Annual Call
The annual submission deadlines are March 31 and September 30.
Bayer HealthCare will inform the results within two months after the respective submission deadline.
Application Procedure
A. Online Submission - Deadline: 31 March and 30 September annually.
• All applications can only be submitted via the electronic submission platform.
• The proposal should include a detailed description of the target and highlight its therapeutic potential.
• Please note that only non-confidential information should be provided.
B. Forward a copy to NUHS Research Office
Contact Us
Please do not hesitate to contact us if you have any enquires.
For any urgent grant matters, you may also contact Ruth at 67723709, or ruth_gao@nus.edu.sg .
